IP Library Granted Patent US 9,284,377
Granted Patent B2
US 9,284,377 · App. 14/744,706 · Granted Mar 15, 2016

MDL-1 ligand

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,284,377
App. No.
14/744,706
Granted
Mar 15, 2016
Kind
B2
Abstract

The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.

Claims (5)

1. A method of depleting a population of T lymphocyte cells comprising contacting the population of T lymphocyte cells with an MDL-1 fusion protein that binds directly or indirectly to a molecule expressed on the T lymphocyte cells wherein the MDL-1 fusion protein comprises an extracellular domain of MDL-1 and a heterologous protein which is an Fc portion of an immunoglobulin molecule.

2. The method of claim 1 , wherein the heterologous protein is human serum albumin.

3. The method of claim 1 , wherein the population of T lymphocyte cells express CD45, CD90, and CD117.

4. The method of claim 3 , wherein the population of T lymphocyte cells further express IL-23R.

5. The method of claim 4 , wherein the population of T lymphocyte cells mediate enthesopathy.

Assignments (1)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →